Future perspectives on the treatment of hepatocellular carcinoma with cisplatin

Table 1 Systemic chemotherapy

Author	Country and region	Publication year	Treatment schedule	n	RR (%)	PFS (M)	MST (M)	1yrs (%)
Falkson et al[7]	USA	1987	CDDP 75 mg/sq q3w	35	< 17	-	3.2	-
Okada et al[4]	Japan	1993	CDDP 80 mg/sq q4w	26	15.4	-	-	-
Nagahama et al[8]	Japan	1997	CDDP	43	9.3	-	-	-
Ji et al[9]	Korea	1996	CDDP 60 mg/sq q4w	30	13.3	-	7.6	23.5
			IFN-α 3MU im for 3 mo
Leung et al[10]	China	2002	CDDP 20 mg/sq, d1-4	149	16.8	-	7.1	-
			DXR 40 mg/sq, d1
			5-FU 400 mg/sq, d1-4
			IFN-α 5MU SC d1-4 q3w
Yang et al[11]	Taiwan	2004	CDDP 80 mg/sq d1	63	23.8	2.5	4.9	-
			Mitoxantrone 6mg/sq d1
			5-FU 450 mg/sq d1-5 q4w
Ikeda et al[12,13]	Japan	2008	CDDP 80 mg/sq d1	82	22.0	3.2	11.2	43.5
		(2005)	Mitoxantrone 6 mg/sq d1
			5-FU 450 mg/sq d1-5 q4w
Parikh et al[14]	India	2005	CDDP 70 mg/sq d1	30	20.0	4.1	4.8	27.0
			GEM 1250 mg/sq d1, 8 q3w
Yeo et al[15]	China	2005	CDDP 20 mg/sq, d1-4	94	20.9	-	8.7	39.0
			DXR 40 mg/sq, d1
			5-FU 400 mg/sq, d1-4
			IFN-α 5MU. SC d1-4 q3w
Kim et al[16]	Korea	2006	CDDP 60 mg/sq d1	53	16.9	2.7	5.7	-
			EPI 50 mg/sq d1
			UFT 400-600 mg/d PO 3w
			leucovorin 75 mg/d PO 3w q4w
Park et al[17]	Korea	2006	CDDP 60 mg/sq, d1	29	24.1	3.7	7.7	-
			DXR 60 mg/sq, d1
			Capecitabine 2 g/sq per day 2w q3w

PO: Per os; SC: Subcutaneous injection; im: Intramuscular injection; CDDP: Cisplatin; DXR: Doxorubicin; EPI: Epirubicin; 5-FU: 5-fluorouracil; UFT: Tegaful-uracil; GEM: Gemcitabine; IFN: Interferon; RR: Response rate; PFS: Progression free survival; MST: Median survival time; 1yrs: 1 year survival rate.